The Value of Androgen Measures for Diagnosing Polycystic Ovary Syndrome (PCOS) in an Unselected Population
Reproductive Sciences · 2025
DOI: 10.1007/s43032-024-01702-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Reproductive Sciences, 2025. Verfasst von L Pace und 3 weiteren Autor:innen. Beteiligte Einrichtung: Dept. of Ob/GynHeersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA. Hauptthemen laut MEDLINE: Polycystic Ovary Syndrome, Androgens, Hyperandrogenism. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
Polycystic Ovary Syndrome (PCOS) is diagnosed by a combination of three features: hyperandrogenism (biochemical and/or clinical), ovulatory dysfunction, and polycystic ovarian morphology, usually detected by ultrasonography. Our study aimed to determine the need for androgen measurements by using hirsutism to establish hyperandrogenism for diagnosing PCOS in a medically unbiased population. Materials and Methods We utilized a pre-existing cohort of unselected (medically unbiased) females aged 18–45 years. All underwent a history and physical, including a modified Ferriman-Gallwey (mFG) hirsutism score. Subjects were categorized clinically as eumenorrheic non-hirsute (CONTROLS), menstrual dysfunction only (OLIGO-ONLY), hirsutism only (HIRSUTE-ONLY), or menstrual dysfunction and hirsutism (OLIGO + HIRSUTE). All subjects underwent measurements of androgens using high-quality assays. CONTROLS established the upper normal limit for androgen levels. We defined PCOS using the NIH 1990 criteria.
Results
Of 462 individuals with complete evaluations, 311 (67.3%) were CONTROLS, 71 (15.4%) were OLIGO-ONLY, 64 (13.9%) were HIRSUTE-ONLY, and 16 (3.5%) were OLIGO + HIRSUTE. Neither HIRSUTE-ONLY nor OLIGO-HIRSUTE women required androgen measures to demonstrate hyperandrogenism. Among OLIGO-ONLY, 19 (26.8%) demonstrated hyperandrogenemia without hirsutism, with White women significantly more likely than Black women to demonstrate this.
Conclusions
In our study of medically unbiased reproductive-aged women using the NIH 1990 criteria for PCOS, only 15.4% of women evaluated (those with menstrual dysfunction only) required androgen measurements. In these women only one-quarter demonstrated hyperandrogenemia. These data provide a strategy to minimize the need for androgen assays, including firstly categorizing subjects by clinical presentation and then assessing circulating androgens in the subgroup with menstrual dysfunction only.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dept. of Ob/GynHeersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
- Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
- Dept. of Ob/GynHeersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA. razziz@uabmc.edu.
- Dept. of Medicine, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA. razziz@uabmc.edu.
- Dept. of Healthcare Organization & Policy, School of Public Health, University of Alabama at Birmingham, Birmingham, AL, USA. razziz@uabmc.edu.
- Dept. of Health Policy, Management, and Behavior, School of Public Health, University at Albany, SUNY, Rensselaer, NY, USA. razziz@uabmc.edu.
Zitieren
APA
Pace, L., Kummer, N., Wallace, M., & Azziz, R. (2025). The Value of Androgen Measures for Diagnosing Polycystic Ovary Syndrome (PCOS) in an Unselected Population. Reproductive Sciences. https://doi.org/10.1007/s43032-024-01702-9
Vancouver
Pace L, Kummer N, Wallace M, Azziz R. The Value of Androgen Measures for Diagnosing Polycystic Ovary Syndrome (PCOS) in an Unselected Population. Reproductive Sciences. 2025. doi:10.1007/s43032-024-01702-9
BibTeX
@article{Pace2025,
author = {Pace, L and Kummer, N and Wallace, M and Azziz, R},
title = {The Value of Androgen Measures for Diagnosing Polycystic Ovary Syndrome (PCOS) in an Unselected Population},
journal = {Reproductive Sciences},
year = {2025},
doi = {10.1007/s43032-024-01702-9}
}
EUVIMED